Exemestane and aromatase inhibitors in the management of advanced breast cancer

Bibliography

• IBRAHIM NK, BUZDAR AU: Aromatase inhibitors: current status. Am.,/ Gin. Oncoi (CCP) (1995) 18:407–417.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, VON MINCKWITZ G: New hormones. In: Textbook of Breast Cancer: A Clinical Guide to TherapyBonadonna G, Hortobagyi GN,Gianni AM (Eds), Dunitz, London, UK (1997):281–304.
   Google Scholar
• EVANS CT, LEDESMA DB, SCHULZ TZ, SIMPSON ER, MENDELSON CR: Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P450 mRNA. Proc. Nati Acad. Sci. USA (1986) 83:6387–6391.
   PubMed Web of Science ®Google Scholar
• HARVEY HA: Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol. (1996)23\(Suppl. 9):33–38.
   Google Scholar
• REED MJ: The role of aromatase in breast tumours. Breast. Cancer. Res. Treat. (1994) 30:7–17.
   PubMedGoogle Scholar
• SIMPSON ER, CLYNE C, RUBIN G et al.: Aromatase — a brief overview. Ann. Rev Physiol. (2002) 64:93–127.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Aromatase inhibitors and inactivators in breast cancer. Br. Med.(2001) 323:880–881.
   PubMedGoogle Scholar
• ••An excellent Editorial providing a succinctsummary on the role of these potent inhibitors of oestrogen synthesis.
   Google Scholar
• SMITH IE, DOWSETT M: Aromatase inhibitors in breast cancer. N Eng]. I Med. (2003) 348(24):2431–2442.A timely review of the current role of aromatase inhibitors and their potential for clinical use.
   Google Scholar
• ALLRED DC, BAUM M, BUZDAR AU et al.: A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J. (2003) 9(3):213–222.
   PubMedGoogle Scholar
• ••This article summarises the conclusions ofa meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer.
   Google Scholar
• GOSS PE: Emerging role of aromatase inhibitors in the adjuvant setting. Jim. Clin. Oncol. (2003) 26(4):S27–S33.
   Google Scholar
• GOSS P: Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control. (2002) 9(2 Suppl.):2–8.
   Google Scholar
• •This article discusses the central role of antiaromatase agents in the management of breast cancer in postmenopausal women. Authors outline the different mechanisms of steroidal and nonsteroidal aromatase inhibitors and their different effects on cellular aromatase activity.
   Google Scholar
• GOSS PE, STRASSER K: Aromataseinhibitors in the treatment and preventionof breast cancer. J. Clin. Oncol (2001) 19:881–894.
   PubMed Web of Science ®Google Scholar
• MILLER WR, DIXON JM: Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin. Breast. Cancer (2000) 1 (Suppl. 1):S9–S14.
   Google Scholar
• DOWSETT M, JONES A,JOHNSTON SRD, JACOBS S, TRUNET P, SMITH IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.Clin. Canc. Res. (1995) 1:1511–1515.
   PubMed Web of Science ®Google Scholar
• GEISLER J, KING N, DOWSETT M et al.: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J. Cancer (1996) 74:1286–1291.
   PubMed Web of Science ®Google Scholar
• GEISLER J, KING N, ANKER G et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. (1998) 4:2089–2093.
   PubMed Web of Science ®Google Scholar
• ••This is the first study revealing near totalaromatase inhibition in vivo with the use of a steroidal aromatase inhibitor and identify exemestane as a promising new drug for the treatment of hormone-sensitive breast cancer.
   Google Scholar
• GEISLERJ, HAYNES B, ANKER G et Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. .1. Clin. Oncol (2002) 20(3):751–757.
   Google Scholar
• ••This study compared the effects of the twonovel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total body aromatisation and plasma oestrogen levels. Letrozole was found to be a more potent suppressor of total body aromatisation and plasma oestrogen levels compared with anastrozole in postmenopausal women with metastatic breast cancer.
   Google Scholar
• CHEN S, ZHOU D, OKUBO T et al.: Breast tumor aromatase: functional role and transcriptional regulation. Endoct: Reim. Cancer (1999) 6:149–156.
   PubMed Web of Science ®Google Scholar
• HARADA N, HONDA SI, HATANO 0: Aromatase inhibitors and enzyme stability. Endoct: Reim. Cancer (1999) 6:211–218.
   Google Scholar
• ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial.Clin. Oncol (2001) 19:3808–3816.
   Google Scholar
• MURRAY P, PITT P: Aromatase inhibition with 4-0HAdrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast. Cancer Res. Treat. (1995) 35:249–253.
   PubMed Web of Science ®Google Scholar
• GEISLER J, JOHANNESSEN DC, ANKDER G et al: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur. .1. Cancer (1996) 32A:789–792.
   PubMed Web of Science ®Google Scholar
• LONNING PE, BAJETTA E, MURRAY R et al.: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A Phase II trial.Clin Oncol (2000) 8(11):2234–2244.
   Google Scholar
• •This paper highlights a lack of cross-resistance between steroidal and nonsteroidal aromatase inhibitors, which may provide the option for their use sequentially in advanced breast cancer at the time of progression.
   Google Scholar
• BERTELLI G, GARRONE 0, MERLANO M: Sequential use of aromatase inactivators and inhibitors inadvanced breast cancer. Annual meeting of the American Society of Clinical Oncology (2002) 238 (Abstract).
   Google Scholar
• BUZDAR A, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer (1998) 83:1142–1152.
   PubMed Web of Science ®Google Scholar
• ••This combined analysis of two trials ofpostmenopausal patients with advanced breast carcinoma has clearlydemonstrated that, after disease progression with tamoxifen, treatment with anastrozole 1 mg/day results in a statistically and clinically significant advantage over a standard treatment with megestrol acetate.
   Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol (1998) 16:453–461.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrates the clinicalsuperiority of the third-generation aromatase inhibitor, letrozole, over megestrol acetate, with a better safety profile.
   Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. I. Clin. Oncol. (2000) 18(7):1399–1411.
   PubMed Web of Science ®Google Scholar
• ••In this study comparing exemestane withmegestrol acetate, time to disease progression, time to treatment failure and overall survival were all significantly better for exemestane than megestrol acetate.
   Google Scholar
• MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Omni (2001) 19:2596-2606 [Erratum: " Clin. Oncol. (2001) 19:33021.
   Google Scholar
• NABHOLTZ JM, BUZDAR A, POLLAK M et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of aNorth American multicenter randomized trial." Clin. Oncol (2000) 18:3758–3767.
   PubMed Web of Science ®Google Scholar
• BONNETERRE J, THORLIMANN B, ROBERTSON JFR et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. j Clin. Oncol (2000) 18:3748–3757.
   PubMed Web of Science ®Google Scholar
• PARIDAENS R, DIRIX L, BEEX L et al: Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized Phase II EORTC trial with a tamoxifen control. Clin. Breast. Cancer (2002) 1(1):519–521.
   Google Scholar
• DIRIX L, PICCART MJ, LOHRISH C et al.: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia & Upjohn. Proc. Am. Soc. Clin. Oncol (2001) 20:29a (Abstract).
   Google Scholar
• THE ATAC (ARIMIDEX, TAMOXIFEN ALONE OR IN COMBINATION) TRIALISTS' GROUP: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131–2139.
   PubMed Web of Science ®Google Scholar
• POWLES TJ, HICKISH T, KANIS JA, TIDY A, ASHLEY S: Effects of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women." Clin. Oncol (1996) 14:78–84.
   PubMed Web of Science ®Google Scholar
• LOVE RR, BARDEN HS, MAZESS RB, EPSTEIN S, CHAPPELL RJ: Effect of tamoxifen on lumbar spine bone mineraldensity in postmenopausal women after 5 years. Arch. Intern. Med. (1994) 154:2585–2588.
   PubMed Web of Science ®Google Scholar
• HARPER-VVYNNE C, ROSS G, SACKS N et al.: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers. Prey. (2002) 11:614–621.
   PubMedGoogle Scholar
• LONNING P: Clinical pharmacokinetics of aromatase inhibitors and inactivators. Pharmacokinet. (2003) 42(7):619–631.
   PubMedGoogle Scholar
• MORTIMER JE, URBAN JH: Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. Oncology (Hunting) (2003) 17(5):652–659.
   PubMedGoogle Scholar
• •Highlights the need to be conscious of the differences between antiaromatase agents and selective oestrogen-receptor modulators and their impact on women's health. More information about the effects of the anti-aromatase agents on normal tissue will become available as data from ongoing adjuvant and chemoprevention trials are reported.
   Google Scholar
• GOSS P, GRYNPAS M, QI S, HU H: The effects of exemestane on bone and lipids in the ovariectomized rat. Presented at the 24th Annual San Antonio Breast Cancer Symposium. San Antonio, USA (2001).
   Google Scholar
• ZILEMBO N, BAJETTA E,MARTINETTI A et al.: Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA) (abstract 707). Eur. J. Cancer. (2001) 37\(Suppl. 6):5193.
   Google Scholar
• BEAR H: Indications for neoadjuvant therapy for breast cancer. Semin. Oncol (1998) 25\(Suppl. 3):3–12.
   Google Scholar
• DIXON JM, ANDERSON TJ, MILLER WR: Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur. J. Cancer. (2002) 38:2214–2221.
   PubMed Web of Science ®Google Scholar
• DIXON JM: Neoadjuvant therapy: surgical perspectives. In: Endocrine Therapy in Breast Cancer. Miller WR, Ingle JR (Eds),Marcel Dekker, Inc., New York(2002):197–212.
   Google Scholar
• SMITH I, DOWSETT M, on behalf of the IMPACT TRIALISTS: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Presented at the 26"' San Antonio Breast Cancer Symosium, San Antonio, Texas, USA, December 3–6 (2003).
   Google Scholar
• MILLER WR, DIXON JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. (2002) 9(Suppl.):9–15.
   Google Scholar
• GIL M: Neoadjuvant exemestane in breast Cancer. Poster presented at the 25h Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 11–14 (2002).
   Google Scholar
• SEMINGLAZOV VF et al.: Exemestane and tamoxifen as neoadjuvant breast cancer therapy: a pilot trial. Poster 9, presented at the Future of Breast Cancer Congress, August, Canada (2003).
   Google Scholar